Clinical Trials on HER2 Positive Advanced Solid Tumors in Hong Kong

Total 116 results

New Beta Innovation Limited

Terminated

A Safety Study of YQ23 in Advanced Solid Tumors Patients

Advanced Solid Tumor

Hong Kong
New Epsilon Innovation Limited

Active, not recruiting

An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia

Advanced Solid Tumor | Relapsed AML | Refractory AML

Hong Kong
Chinese University of Hong Kong

Completed

MOSE to Improve the Diagnostic Accuracy During EUS-guided FNA Using a 19-gauge Needle for Solid Lesions

Solid Tumor

Hong Kong
AstraZeneca

Completed

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

China
Amgen

Active, not recruiting

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

Taiwan, Hong Kong
Organisation for Oncology and Translational Research

Unknown

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

ER Positive, HER2 Negative Breast Cancer

China
ASLAN Pharmaceuticals

Completed

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

Solid Tumor

Taiwan, Hong Kong
The University of Hong Kong

Completed

Comparing the Impact of Cancer on Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia

Childhood Solid Tumor

Hong Kong
Hong Kong Children's Hospital
The University of Hong Kong

Recruiting

Propofol vs Sevo for Paediatric Tumor Surgery

Carcinoma | Cancer | Solid Tumor | Malignancy

Hong Kong
Novartis Pharmaceuticals

Completed

An East Asian Study of LDE225

Medulloblastoma | Basal Cell Carcinoma | Advanced Solid Tumor Cancers

Taiwan, Hong Kong, Japan
Harbour BioMed US, Inc.

Completed

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia, China, Hong Kong
CStone Pharmaceuticals

Completed

A Study of CS1002 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

Hong Kong, Australia
Novartis Pharmaceuticals

Completed

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Japan, Hong Kong, Singapore
Novartis Pharmaceuticals

Recruiting

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Advanced Solid Tumors

Switzerland, Korea, Republic of, Belgium, Canada, Germany, Italy, Spain, United States, Hong Kong, Hungary, China, Czechia, Taiwan, France, Poland, Thailand, Netherlands
Abion Inc

Recruiting

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Advanced Solid Tumors

Korea, Republic of, Taiwan, United States
Treadwell Therapeutics, Inc
TIO Discovery Engine

Recruiting

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

United States, Hong Kong, Canada
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Breast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid Tumors

United States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
Novartis Pharmaceuticals

Terminated

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Solid Tumors

United States, Taiwan, Spain, Canada, Italy, Singapore, Japan, Hong Kong
Pfizer

Terminated

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Advanced Breast Cancer (Parts 1 and 2) | Advanced Pancreatic Cancer (Part 1) | Advanced Colorectal Cancer (Part 1) | Advanced Cholangiocarcinoma (Part 1) | Advanced Glioblastoma Multiforme (Part 1)

United States, Spain, Hong Kong, Belgium, Australia, France
Novartis Pharmaceuticals

Completed

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Advanced Solid Tumors

United States, Canada, France, Taiwan, Belgium, Spain, Singapore, Italy, Australia, Hong Kong, Germany, Japan
Ningbo Newbay Technology Development Co., Ltd

Recruiting

A Study of NB003 in Patients With Advanced Malignancies

Advanced Solid Tumor

United States, Spain, China, Korea, Republic of, France, United Kingdom
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Liver Failure | Advanced or Metastatic Solid Tumor

France, United States
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Breast Cancer | Advanced Malignant Solid Tumors

United States, Taiwan, United Kingdom, Hong Kong, Belgium, France, Spain, China, Netherlands, Poland, Sweden
Aadi Bioscience, Inc.

Recruiting

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Malignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic Neoplasm

Korea, Republic of, United States, Puerto Rico
Amgen

Recruiting

AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP)

Advanced MTAP-null Solid Tumors

United States, Canada, Taiwan, Switzerland, United Kingdom, Korea, Republic of, Germany, Austria, France, Belgium, Australia, Hong Kong, Japan
ORIC Pharmaceuticals

Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Solid Tumors

Korea, Republic of, United States, Australia, Taiwan, Poland, Canada, Hong Kong, United Kingdom
Turning Point Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, China, Japan, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, Korea, Democratic People's Republic of, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Taiwan, United Kingdom
Pfizer

Terminated

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Genes, BRCA 1

United States, Belgium, Spain, Denmark, Japan, France, Italy, Netherlands, United Kingdom
3D Medicines (Beijing) Co., Ltd.

Withdrawn

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

China
MacroGenics

Completed

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors

Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
Miller Children's & Women's Hospital Long Beach
Children's Hospital of Orange County

Recruiting

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence (Metronomic)

Solid Tumor

United States
Olema Pharmaceuticals, Inc.

Recruiting

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast Cancer

United States, Korea, Republic of, Australia, Taiwan, Hong Kong, Malaysia, Thailand, Argentina, Belgium, Portugal, Italy
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib in Patients With Specific FGFR Aberrations

Advanced or Metastatic Solid Tumor | Advanced or Metastatic Gastric or Gastroesophageal Cancer | Myeloid or Lymphoid Neoplasms (MLN)

United States, Spain, Turkey, Hong Kong, Korea, Republic of, Belgium, Japan, Netherlands, France, Germany, Italy, Sweden, United Kingdom, Portugal, Singapore
AstraZeneca

Active, not recruiting

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (SERENA-2)

Advanced ER-Positive HER2-Negative Breast Cancer

United States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
Hoffmann-La Roche

Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Belgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, Hungary, Indi...
Spectrum Pharmaceuticals, Inc

Terminated

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Breast Cancer | Colorectal Cancer | Solid Tumor | Glioblastome Multiforme

United States
Effector Therapeutics

Completed

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Solid Tumors

United States
Hoffmann-La Roche

Completed

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer (PHranceSCa)

HER2-Positive Early Breast Cancer

United States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
Omega Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I)

Hepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-Resectable

United States, Hong Kong, Korea, Republic of, Singapore, Taiwan
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

United States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
Gilead Sciences

Active, not recruiting

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors (TROPiCS-03)

Metastatic Solid Tumor

United States, Spain, France, Hong Kong, Australia, Belgium, Taiwan, Canada
Novartis Pharmaceuticals

Completed

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Acute Lymphoblastic Leukemia (ALL) | Chronic Myelogenous Leukemia (CML) | Metastatic Gastrointestinal Stromal Tumors (GIST) | Receptor Tyrosine Kinase (KIT) Mutated Melanoma

Italy, United Kingdom, Canada, Singapore, Netherlands, France, Korea, Republic of, United States, Slovakia, Hungary, Russian Federation, Hong Kong, Spain, Israel, Sweden, Austria
Hoffmann-La Roche

Recruiting

Screening Study for Participants With Malignant Tumors

Solid Tumors

Korea, Republic of, Belgium, Canada, Australia, Brazil, Taiwan, Japan, Singapore, Thailand, Italy, Spain, Turkey, United States, Costa Rica, Hong Kong, Poland, Chile, Serbia, United Kingdom, New Zealand, Colombia, France, Norway
Zhujiang Hospital
Guangdong Xiangxue Precision Medical Technology Co., Ltd.; Xiangxue Life Science... and other collaborators

Completed

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

Solid Tumor | Breast Cancer Stage IV | Gastric Cancer Stage IV | Ovarian Cancer Stage IV | Liver Cancer Stage IV | Esophageal Cancer, Stage IV | Bone and Soft Tissue Tumors | Bladder Carcinoma Stage IV | Prostate Carcinoma Stage IV | Thyroid Cancer Stage IV

China
Novartis Pharmaceuticals

Completed

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Solid Tumors

Germany, United States, Netherlands, Spain, Canada, Hong Kong, Italy, Singapore, Australia, Israel, Korea, Republic of, Taiwan, France, Norway, Thailand
Genentech, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
Hoffmann-La Roche

Recruiting

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Solid Tumors

Belgium, United States, Australia, Canada, Japan, Korea, Republic of, United Kingdom, Germany, Taiwan, China, Puerto Rico, Israel, Singapore, Spain, Brazil, Portugal, South Africa, Denmark, Italy, Poland, Hong Kong, France, New Zealand and more
National Cancer Institute (NCI)

Completed

Fenretinide in Treating Children With Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Neuroblastoma

United States, Australia
Pfizer

Active, not recruiting

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Ovarian Cancer | NSCLC | Solid Tumors | Urothelial Cancer | Advanced Malignancies

Hungary, Spain, United States, Canada, Taiwan, Japan, Serbia, Italy, New Zealand, Australia, Mexico, Russian Federation, United Kingdom, France, Korea, Republic of, Belgium, Poland, Denmark, Israel
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Registration and Informed Consent Study for the Childhood Cancer Research Network

Unspecified Childhood Solid Tumor, Protocol Specific

United States, Canada

Clinical Trials on HER2 Positive Advanced Solid Tumors in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations